CoChat

A Double‐Blind, Placebo‐Controlled Study of Naltrexone in the Treatment of Alcohol‐Dependence Disorder: Results from a Multicenter Clinical Trial

Guardia, José, Caso, Carlos, Arias, Francisco, Gual, Antoni, Sanahuja, Jordi, Ramírez, Marisa, Mengual, Ildefonso, Gonzalvo, Begoña, Segura, Lidia, Trujols, Joan, Casas, Miguel · 2002 · Alcoholism: Clinical and Experimental Research
Cited by 99

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Background A 12‐week, multicenter, double‐blind, randomized, parallel‐group clinical trial to compare naltrexone and placebo was carried out to determine the efficacy, safety, and tolerability of naltrexone together with a psychosocial intervention in the treatment of alcoholism. Methods A total of 202 alcohol‐dependent patients were assigned to 12 weeks’ treatment with either naltrexone or placebo. The relapse rate was evaluated by means of intention‐to‐treat analyses. Alcohol consumption, craving, adverse events, and changes in the biochemical markers of heavy drinking and possible toxicity were evaluated in the 192 patients who were considered to be assessable. Results The survival function for patients who were treated with naltrexone was significantly better than that of the patients who were treated with placebo (Kaplan‐Meier log rank = 4, df = 1, p < 0.05). In addition, 7.9% of patients who were treated with naltrexone relapsed as compared with 18.8% of those who received placebo [χ 2= 5.89, df = 2, p= 0.050]. In comparing naltrexone with placebo‐treated patients, the most common adverse events were abdominal pain [8.6% vs. 1%; (χ 2= 6.1, df = 1, p < 0.05)] and headache [7.5% vs. 1% (χ 2= 5.1, df = 1, p < 0.05)]. Conclusions Naltrexone was well‐tolerated, as the rate of adverse events was low, and safe, as it did not interfere with the normalization of biochemical markers of heavy drinking or alter liver function markers. Naltrexone seemed to reduce relapse rate to heavy drinking, but we found no differences in other alcohol consumption variables between naltrexone‐ and placebo‐treated groups. Although the naltrexone group showed a tendency to consume fewer drinks per drinking day and had a longer time to first drink, differences were not statistically significant.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1530-0277.2002.tb02682.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 99

Metadata

Authors
Guardia, J., Caso, C., Arias, F., Gual, A., Sanahuja, J., Ramírez, M., Mengual, I., Gonzalvo, B., Segura, L., Trujols, J., & Casas, M.
Venue
Alcoholism: Clinical and Experimental Research
Publisher
Wiley
Published
2002-09
Volume
26
Issue
9
Pages
1381-1387
ISSN
  • 0145-6008 (ISSN-L)
  • 1530-0277
OpenAlex
W4232533678
Cited by
99
References
4
FWCI
5.47
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Double‐Blind, Placebo‐Controlled Study of Naltrexone in the Treatment of Alcohol‐Dependence Disorder: Results from a Multicenter Clinical Trial. https://app.cochat.ai/papers/10.1111/j.1530-0277.2002.tb02682.x
The paper
Guardia, J., Caso, C., Arias, F., Gual, A., Sanahuja, J., Ramírez, M., Mengual, I., Gonzalvo, B., Segura, L., Trujols, J., & Casas, M. (2002). A Double‐Blind, Placebo‐Controlled Study of Naltrexone in the Treatment of Alcohol‐Dependence Disorder: Results from a Multicenter Clinical Trial. Alcoholism: Clinical and Experimental Research. https://doi.org/10.1111/j.1530-0277.2002.tb02682.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.